Study of Clotrimazole and Hydroxyurea in Patients With Sickle Cell Syndromes
NCT00004404 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2015-03-25
Summary
OBJECTIVES:
Determine the effectiveness of the combined use of clotrimazole and hydroxyurea on a specific panel of red cell characteristics in patients with sickle cell syndromes.
Conditions
Interventions
- DRUG
-
clotrimazole
- DRUG
-
hydroxyurea
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Carlo Brugnara · Boston Children's Hospital
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1997-04-30
- Completion
- 2002-09-30
Countries
- United States
Study Locations
More Related Trials
-
Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease
NCT06818266 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Hydroxyurea and Transfusion
NCT03644953 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease
NCT00842088 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Long Term Effects of Hydroxyurea Therapy in Children With Sickle Cell Disease
NCT00305175 ·Status: COMPLETED
-
A Sickle CEll Disease ComplicatioN Trial
NCT02604368 ·Status: UNKNOWN ·Phase: PHASE3
-
Hydroxyurea in Young Children With Sickle Cell Anemia
NCT00519701 ·Status: COMPLETED ·Phase: NA
-
Novel Use Of Hydroxyurea in an African Region With Malaria
NCT01976416 ·Status: COMPLETED ·Phase: PHASE3
-
Use of Macrolides in Acute Chest Syndrome: A Multicenter Retrospective Study
NCT07037706 ·Status: COMPLETED
-
A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia.
NCT00040677 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Learn About Sickle Cell Disease In Adult Patients
NCT05407805 ·Status: COMPLETED
-
Inhaled Nitric Oxide for Pediatric Painful Sickle Crisis
NCT00142051 ·Status: TERMINATED ·Phase: PHASE2
-
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
NCT06546670 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Effects of HQK-1001 in Patients With Sickle Cell Disease
NCT01601340 ·Status: TERMINATED ·Phase: PHASE2
-
Pilot Study on the Effects of Intravenous Ketamine on Acute Pain Crisis in Patients With Sickle Cell Disease
NCT00252122 ·Status: TERMINATED ·Phase: PHASE4
-
Shared-Decision Making for Hydroxyurea
NCT03442114 ·Status: COMPLETED ·Phase: NA
-
Sickle Cell Disease: A Retrospective Chart Review
NCT01441375 ·Status: COMPLETED
-
Hydroxyurea for the Treatment of Patients With Sickle Cell Anemia
NCT00001197 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Hydroxyurea to Treat Sickle Cell Disease
NCT02868138 ·Status: COMPLETED
-
Risk Clinical Stratification of Sickle Cell Disease in Nigeria, Assessment of Efficacy/Safety of Hydroxyurea Treatment
NCT02149537 ·Status: COMPLETED ·Phase: PHASE4
-
Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation
NCT04093986 ·Status: RECRUITING
-
SMYLS Multi-site Trial
NCT06035939 ·Status: RECRUITING ·Phase: NA
-
Hydroxyurea Management in Kids: Intensive Versus Stable Dosage Strategies
NCT03020615 ·Status: COMPLETED ·Phase: PHASE2
-
Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)
NCT03263559 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
NCT01506544 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Different Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell Disease
NCT01987908 ·Status: TERMINATED ·Phase: PHASE2